71 results about "Rate of infusion" patented technology

A method and apparatus for reducing the workload of titrating drug to effect while leaving clinician users in control of a related procedure is described. A drug delivery device is controlled to achieve a target drug concentration at a selected site in the patient or a predetermined infusion rate waveform. The time profile of the target drug concentration or a predetermined infusion rate waveform is controlled by a drug state model that uses clinical heuristics to implement safe, pre-defined changes in the target drug concentration or infusion rate and user-commanded changes in target drug concentration or infusion rate. The invention allows time to assess the response of the patient to changes in drug level by making small incremental and conservative changes in drug level over time.

Implantable osmotic pump devices and systems include multiple osmotic pumps and/or semipermeable membranes to extend the useful life cycle and functionality of the drug delivery system. Use of an implantable system including multiple implantable osmotic pumps allows different drugs to be administered from the same implanted system. One or more of the semipermeable membranes of the system may be initially sealed by an overlying impermeable membrane upon implantation of the system into the patient. When the patient develops a tolerance to a first drug or to a first dose of the first drug, the impermeable membrane may be breached, to expose the underlying semipermeable membrane to the osmotic pressure of the patient at the implant site. This causes the infusion rate to increase, thereby providing the patient with the needed relief and/or other desired therapeutic effect. In the case of a multiple pump system, breaching an impermeable membrane may cause the infusion of a second drug. The second drug may potentiate a therapeutic effect (such as an analgesic effect) of the first drug, as is the case with Sufentanil and Clonidine.

A medical device known as an implantable therapeutic substance delivery device is configured for implanting in humans to deliver a therapeutic substance such as pharmaceutical compositions, genetic materials, and biologics to treat a variety of medical conditions such as pain, spastisity, cancer, and many other conditions. The therapeutic substance delivery device has a permanent magnet solenoid pump that is energy efficient, accurate, small, compatible with therapeutic substances, and has many other improvements. The implantable therapeutic substance delivery device has a housing, a therapeutic substance reservoir, a power source, electronics, and a permanent magnet solenoid pump. The therapeutic substance reservoir is configured to contain a therapeutic substance and is coupled to the housing. The power source is carried in the housing to power the electronics and solenoid pump. The electronics are coupled to the solenoid pump and the solenoid pump is coupled to the therapeutic substance reservoir. The permanent magnet solenoid pump is configured for pumping therapeutic substance from the therapeutic substance reservoir through an infusion outlet at a programmed infusion rate. Many embodiments of the permanent magnet solenoid pump and its methods of operation are possible.

A System manages IV pumps so that clinicians automatically receive alerts, decisions, and actions required to maintain a patient IV medication therapy according to a prescribed treatment protocol. An infusion pump monitoring system, includes an acquisition processor for acquiring fluid infusion parameters comprising a patient identifier, infusion fluid identifier and a rate of fluid infusion, for administration of an infusion fluid to a patient at a point of care using an infusion pump. The system also includes a repository of patient medical record information. A fluid infusion monitor uses acquired fluid infusion parameters for automatically searching a patient medical record in the repository for information concerning rate of fluid infusion of a particular infusion fluid and determining if a rate of a previously administered dose of the particular infusion fluid was lower than a rate indicated in the fluid infusion parameters. An interface processor automatically initiates generation of a message indicating a potential adverse reaction to the particular infusion fluid in response to a determination of a lower rate being employed for previously administering the particular infusion fluid.

The system for controlling body fluids overcomes the limitations of the prior art by automatically infusing diuretic and/or other drugs into a human patient. In one approach, the rate of infusion of the diuretic is adjusted based on a measured biological parameter of the patient. For example, this biological parameter can be transmitted wirelessly to a portable diuretic infusion device attached to the patient.

A patient hydration system and method wherein hydration fluid is administered to a patient and the patient's urine output is measured either by weight or some other suitable way. A controller is responsive to the patient's urine output measurement and configured to control the infusion rate to hydrate the patient based on the patient's urine output. The controller also detects abnormal patient urine output measurements and initiates corrective action in response.

An erosion-resistant capillary chip for use with in an infusion pump that is made from a silicon substrate having a first surface that includes a micro groove etched therein and a glass plate laminated to the first surface. The glass plate covers the micro groove so that a micro fluid conduit is created. The glass plate includes an inlet bore that connects with the micro fluid conduit and the silicon substrate includes an outlet bore that connects with the micro fluid conduit so that a drug solution entering the inlet bore from the infusion pump may pass through the micro fluid conduit at a restricted flow rate to the outlet bore and thereafter to a target site of a patient. The micro groove includes a passivation layer made from silicon nitride or silicon carbide that protects the micro groove against erosion from passing fluids having high basic or high acidic pH levels. A method for making the capillary chip is disclosed, as well as an infusion pump incorporating the improved capillary chip.

An infusion system and pump with configurable closed loop delivery rate catch-up including an infusion system having a medication management unit and a medical device. The medication management unit has programming code to: provide a graphical user interface for modifying a drug library; receive a catch-up rate factor; update the drug library with the catch-up rate factor; and transmit the updated drug library to the medical device. The medical device has programming code to: receive the updated drug library; receive a desired infusion rate; calculate expected accumulated infusion volume from the desired infusion rate; request delivery of the infusion at the desired infusion rate; determine actual accumulated infusion volume at a particular time; increase the infusion rate by the catch-up rate factor to generate a catch-up infusion rate when at the particular time the actual accumulated infusion volume is less than expected; and request infusion at the catch-up infusion rate.

The invention provides an ornidazole injection. The ornidazole injection has the advantages of high stability, low impurity content, pH value that is closer to the human physiological pH value, low incidence rate of infusion pain, infusion phlebitis and other adverse reactions, etc.

A liquid may be aged and infused using a wooden infusion apparatus having grain oriented along a longitudinal axis of a rod. One preferred infusion apparatus comprises machining a grain oriented wooden cylinder into the shape of a spiral having a longitudinal central axis. A preferred method is disclosed for continuously machining wooden rods into spirals, and subsequently toasting them. Another infusion apparatus comprises a plurality of wooden discs connected by a longitudinal central axis in the form of a rod, the wooden discs which are toasted. The present invention allows for more control over the time required to properly age the wine and to impart the wood flavor by giving the producer more control over the amount of wood surface area that is exposed to the wine. The rate of infusion is increased substantially when the wood grain extends along the longitudinal axis of the infusion apparatus. The shape and size of the infusion apparatus may be customized to fit any container from a huge wine barrel to a small liquor bottle. Additionally, the infusion spiral may be connected to a lid or bung of a container, and may thereby be removed when desired by merely opening the lid or bung. The infusion spiral can be replaced, by this same manner, with a different type of wood infusion spiral or a fresher infusion spiral to enhance the flavor imparted to the wine without having to fish around in the container for the infusion spiral.

Methods and systems for infusing a cooled infusate to a target location in a patient are described. A temperature of the blood and infusate admixture upstream of the catheter as well as at other locations along the catheter may be monitored and a feedback system utilized to control the volume, temperature, and/or infusion rate of the infusate so as to achieve a predetermined temperature at the target location. Control may also be based on the patient's native vessel flow rate. The system may monitor or calculate hematocrit upstream of the catheter and adjust infusion so as to provide sufficient oxygenation of the blood and infusate admixture. The system may also monitor reflux of the infusate past a distal end of the catheter and reduce infusion upon the detection of reflux.

Herein is disclosed a method of treating neoplastic disease, including cancer, comprising administering a pharmaceutical composition, the pharmaceutical composition comprising a highly concentrated aqueous solution of phenylacetylglutamine and phenylacetylisoglutamine in a 4:1 ratio, at an infusion rate of from 100 mL/hr to 400 mL/hr. In a further embodiment, herein is also disclosed a method of treating neoplastic disease, including cancer, comprising administering a pharmaceutical composition, the pharmaceutical composition comprising a highly concentrated aqueous solution of phenylacetate and (phenylacetylglutamine or phenylacetylisoglutamine) in a 4:1 ratio, at an infusion rate of from 100 mL/hr to 400 mL/hr. Herein are also disclosed the pharmaceutical compositions used in the above methods.

The invention discloses a medicine infusion device having multiple infusion modes. The medicine infusion device comprises a medicine storage unit, a piston, a screw rod, a driving module, a power module and a control module; the piston is arranged in the medicine storage unit; the piston is connected with the screw rod; the driving module at least comprises a first driving unit and a second driving unit, which are matched with each other to operate; the second driving unit drives the screw rod to advance; the power module is connected with the first driving unit; the control module is connected with the power module; and the control module controls the power module to apply different acting forces to the first driving unit, so that the first driving unit has multiple different operation modes, and the infusion device has multiple different unit infusion amounts or infusion rates. A user can select different infusion modes to infuse medicines, so that the user experience is enhanced.

The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts 2 months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety. In this embodiment, fluids, heparin and/or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.